Viking Therapeutics (NasdaqCM:VKTX) 2025 Conference Transcript

Viking Therapeutics Conference Call Summary Company Overview - Company: Viking Therapeutics (NasdaqCM: VKTX) - Focus: Metabolic and endocrine disorders - Location: San Diego, California - Employees: Approximately 55 Key Programs and Developments - VK2735: A GLP-1 GIP dual agonist for obesity - Currently in Phase III program called the VANQUISH program [4][35] - Oral formulation recently completed Phase II study [4][35] - Amylin Agonist: Expected to file an IND in the first quarter of 2026 [5][36] - VK2809: A thyroid receptor beta agonist that has completed a Phase IIb study in NASH [5] - VK0214: Another thyroid receptor beta agonist that has completed a Phase Ib study in X-linked adrenoleukodystrophy [5] Clinical Data and Efficacy - VK2735 Oral Formulation: - Phase II study showed up to 12.2% body weight reduction after 13 weeks of dosing [20][29] - Weight loss maintained for four weeks after the last dose [10][20] - Excellent tolerability with most adverse events classified as mild to moderate [21][29] - VK2735 SubQ Formulation: - Phase II study showed weight loss of 9% to 15% from baseline after 13 weeks [25][30] - Durable weight loss observed 21 days after the last dose [23][30] - Excellent tolerability with 98% of adverse events classified as mild to moderate [24][30] Pipeline and Future Studies - VANQUISH Phase III Studies: - VANQUISH I: Completed enrollment, focusing on obesity [30][35] - VANQUISH II: Expected to complete enrollment in the first quarter of next year [30][35] - Maintenance Study: Ongoing with a focus on transitioning from weekly to monthly dosing [33][34] Financial Overview - Cash Position: Over $700 million as of the third quarter, expected to fund through the VANQUISH Phase III data readouts [34][35] Additional Insights - The company is prioritizing mid-range doses for the oral formulation based on pharmacokinetics and gastrointestinal tolerability [37] - The potential for transitioning from SubQ to oral dosing to maintain weight loss is being explored [37] This summary encapsulates the key points from the Viking Therapeutics conference call, highlighting the company's focus on metabolic disorders, clinical program advancements, and financial health.